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Abstract 46 
Peptide receptor radionuclide therapy (PRRT) is an established treatment of metastatic 47 
neuroendocrine tumors grade 1-2 (G1-G2). However, its possible benefit in high-grade 48 
gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN G3) is unknown. We therefore 49 
aimed to assess the benefits and side effects of PRRT in patients with GEP NEN G3. We performed 50 
a retrospective cohort study at 12 centers to assess efficacy and toxicity of PRRT in patients with 51 
GEP NEN G3. Outcomes were response rate, disease control rate, progression-free survival (PFS), 52 
overall survival (OS) and toxicity. We included 149 patients (primary tumor: pancreatic n=89, 53 
gastrointestinal n=34, unknown n=26). PRRT was 1st-line (n=30), 2nd-line (n=62) or later line 54 
treatment (n=57). Of 114 patients evaluable, 1% had complete response, 41% partial response, 38% 55 
stable disease and 20% progressive disease. Of 104 patients with documented progressive disease 56 
before PRRT, disease control rate was 69%. The total cohort had median PFS of 14 months and OS 57 
29 months. Ki-67 21-54% (n=125) vs. Ki-67≥55% (n=23): PFS 16 vs. 6 months (p<0.001) and OS 58 
31 vs. 9 months (p<0.001). Well (n=60) vs. poorly-differentiated NEN (n=62): PFS 19 vs. 8 months 59 
(p<0.001) and OS 44 vs.19 months (p<0.001). Grade 3-4 hematological or renal toxicity occurred in 60 
17% of patients. This large multicenter cohort of patients with GEP NEN G3 treated with PRRT 61 
demonstrates promising response rates, disease control rates, PFS and OS as well as toxicity in 62 
patients with mainly progressive disease. Based on these results, PRRT may be considered for 63 
patients with GEP NEN G3. 64 
 65 
 66 
 67 
  68 
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Introduction 69 
Neuroendocrine neoplasms (NEN) are a very heterogeneous entity classified according to primary 70 
tumor location, stage, proliferation rate and differentiation. The 2010 World Health Organization 71 
(WHO) Classification grades NEN according to the proliferation index Ki-67; ≤ 2% (Grade 1, G1), 72 
3-20% (G2) and > 20 % (G3) (Bosman, et al. 2010). G1-G2 were collectively referred to as 73 
neuroendocrine tumors (NET) and G3 as neuroendocrine carcinoma (NEC). The classification is 74 
strongly prognostic, but is also used to guide treatment decisions. In 2017, WHO refined the 75 
classification of pancreatic NEN; G3 tumors are further classified as well (NET G3) and poorly 76 
differentiated (NEC) (Kloppel, et al. 2017), and a similar expansion to gastrointestinal (GI) G3 77 
tumors is anticipated in the next WHO classification. The NET category is now only used for well-78 
differentiated tumors regardless of their proliferation index (G1-G3), whereas the NEC category is 79 
used for poorly differentiated high-grade neuroendocrine carcinomas (G3). The terminology of 80 
NEN G3 relates to all high-grade (G3, Ki-67 >20%) neuroendocrine malignancies; i.e. both NET 81 
G3 and NEC. 82 
Gastroenteropancreatic (GEP) NENs G3 are rare, highly malignant, with poor 83 
prognosis and limited therapeutic options (Garcia-Carbonero, et al. 2016; Ilett, et al. 2015; Sorbye, 84 
et al. 2014). The majority of patients have metastases at the time of diagnosis and median overall 85 
survival (OS) is less than 6 months including all patients (Dasari, et al. 2018). Platinum-based 86 
chemotherapy is the standard treatment in metastatic disease with response rates of 30-35%, 87 
progression-free survival (PFS) of 4-5 months and OS 11-14 months (Heetfeld, et al. 2015; Sorbye, 88 
et al. 2013; Walter, et al. 2017; Yamaguchi, et al. 2014). 89 
In metastatic GEP NET G1-G2, peptide receptor radionuclide therapy (PRRT) 90 
targeting somatostatin receptors has been used with excellent results for the last two decades in 91 
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Europe and Israel (Bodei, et al. 2011; Imhof, et al. 2011; Kwekkeboom, et al. 2008; Pfeifer, et al. 92 
2011; Romer, et al. 2014). The recent NETTER-1 phase 3 trial of patients with somatostatin 93 
receptor imaging (SRI) positive NET G1/G2 supports this approach (Strosberg, et al. 2017). In 94 
contrast, PRRT has generally not been recommended for GEP NEN G3 based on expectance of low 95 
expression of somatostatin receptors and rapid growth behavior. According to guidelines, PRRT can 96 
be considered in SRI-positive NET G3, but data are lacking (Garcia-Carbonero et al. 2016). PRRT 97 
could, however, be a relevant therapeutic option for NEN G3 since SRI positivity has been reported 98 
for both NET G3 and NEC (Heetfeld et al. 2015; Raj, et al. 2017; Sorbye et al. 2013; Velayoudom-99 
Cephise, et al. 2013), as well as having expression of somatostatin receptor 2A on 100 
immunohistochemistry (Konukiewitz, et al. 2017). 101 
Randomized large studies to assess the benefit of specific treatments are often not 102 
feasible to perform in very rare diseases. Large retrospective datasets may then initially be the only 103 
way on which to base treatment decisions. In a large multicenter international cooperation, we 104 
therefore collected retrospectively the outcomes after PRRT in patients with GEP NEN G3.   105 
 106 
Methods 107 
Patients 108 
At 12 university hospitals, we retrospectively included patients that fulfilled the following criteria: 109 
1) GEP NEN or NEN of unknown primary with dominance of abdominal metastases, 2) Ki-67 > 110 
20%, and 3) treated with PRRT. Data on demographics, diagnosis, previous treatments, PRRT, 111 
outcome and toxicity were registered. SRI (
68
Ga-somatostatin analogue positron emission 112 
tomography [PET]/computer tomography [CT], or 
111
In-octreotide or 
99m
Tc-tektrotyd scintigraphy) 113 
results were reported as tumor uptake in relation to liver uptake (none, < liver, = liver or > liver) 114 
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and used as a surrogate for somatostatin receptor density. 
18
F-Flour-Deoxy-Glucose (FDG) PET/CT 115 
results were reported as tumor uptake present or not (positive or negative by qualitative 116 
assessment). Histological examination included chromogranin A (CgA) and synaptophysin staining, 117 
Ki-67% in hot-spots, and tumor differentiation (poor, intermediate and well). Most of the centers 118 
have specific NET pathologists and in cases where differentiation was lacking in the original 119 
pathology report, a reclassification was done if sections were available. Plasma values of 120 
chromogranin A, lactate dehydrogenase (LDH) and alkaline phosphatase (ALP) obtained at the time 121 
of first PRRT were reported.  122 
Patients were grouped according to Ki-67 index (21-54% and ≥ 55%) based on the 123 
Nordic NEC study and other reports (Garcia-Carbonero et al. 2016; Sorbye, et al. 2018; Sorbye et 124 
al. 2013; Thang, et al. 2018). Furthermore, patients were grouped by combined Ki-67% and 125 
differentiation: Ki-67: 21-54% and well-differentiated tumor (NET G3) vs. Ki-67: 21-54% and 126 
poorly differentiated tumor (NEC; Ki-67 21-54%) vs. Ki-67 ≥ 55% and poorly differentiated tumors 127 
(NEC; Ki-67 ≥ 55%) (Milione, et al. 2017).  128 
Ethical committee approval was obtained in accordance with regional guidelines 129 
(either approval of the study or exempt of application due to the retrospective design). Regional 130 
ethics committees for participating centers are Rigshospitalet (Videnskabsetisk Komité, Region 131 
Hovedstaden) and Aarhus University Hospital (Videnskabsetisk Komité, Region Midt), Denmark; 132 
University Hospital Bonn (Ethikkommission an der Medizinischen Fakultät der 133 
RheinischenFriedrich-Wilhelms-Universität Bonn) and University Hospital Gießen and Marburg 134 
(Ethics Committee of the Philipps-University Marburg, Medicine), Germany; Hadassah-Hebrew 135 
University Medical Center (Hadassah-Hebrew University Medical Center Institutional Ethical 136 
Committee), Israel; European Institute of Oncology (Ethics Committee), Italy; Erasmus Medical 137 
Center (Medical Research and Ethics Committee, Rotterdam), The Netherlands; MSWiA Hospital 138 
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Warsaw (Komisja Etyki i Nadzoru nad Badaniami na Ludziach), Poland; Uppsala University 139 
Hospital (Uppsala Regionala Etikprövningnämnden), Sweden; University Hospital Basel 140 
(Ethikkommission beider Basel), Switzerland; Churchill Hospital (Oxford Research and Ethics 141 
Committee) and Imperial College London (Regional Ethics Committee of Wales), United Kingdom. 142 
Patients gave informed consent before receiving PRRT.  143 
 144 
Treatment 145 
Patients received PRRT according to local guidelines at their respective institution. In general, 146 
treatment was given intravenously and consisted of a radioisotope (
177
Lutetium, 
90
Yttrium or 
111 147 
Indium) conjugated with a somatostatin analogue (octreotide or octreotate). Patients were planned 148 
to a series of PRRT, typically consisting of four cycles each and separated by approximately 8 149 
weeks. The intended cumulative activity was calculated by taking renal function and bone marrow 150 
irradiation into account. To reduce renal irradiation, patients were pretreated with an intravenous 151 
amino-acid solution. Planned PRRT cycles were discontinued in case of progression of disease or 152 
adverse effects limiting further cycles.      153 
  154 
Outcomes 155 
Response rate (RR) was defined as complete response (CR) or partial response (PR) according to 156 
the response evaluation criteria in solid tumors (RECIST 1.1) (Eisenhauer, et al. 2009). Disease 157 
control rate (DCR) was defined as CR or PR in all patients or stable disease (SD) in patients with 158 
progressive disease (PD) at the start of PRRT. PFS was time from first cycle of PRRT to disease 159 
progression radiologically by RECIST 1.1, or clinically assessed by a physician [i.e. worsening of 160 
performance status due to NEN]. If no progression was documented, date of death or date last 161 
Side 9 af 30 
 
follow-up if alive was used. OS was time from first cycle of PRRT to death or date of last follow-up 162 
if still alive. Toxicity was reported as acute if occurring during PRRT and as long-term if occurring 163 
after PRRT and within 1 year of PRRT. Toxicity was graded according to the Common 164 
Terminology Criteria for Adverse Events v.4, reporting grade 3-4 only.  165 
 166 
Statistics  167 
Continuous variables are reported as median and range. By means of Kaplan-Meier estimation, PFS 168 
and OS was calculated and reported as median with 95 % confidence intervals (CI). Log-rank test 169 
was used to compare PFS and OS estimates between groups. Cox regression analysis was 170 
performed for PFS and OS with covariates: age, gender, performance status, SRI tumor uptake, Ki-171 
67 (dichotomized), primary tumor site, tumor morphology (well vs. poorly differentiated, excluding 172 
the intermediate group due to few cases), plasma LDH and plasma ALP. P-values < 0.05 were 173 
considered statistically significant. All analyses were performed using SPSS statistics 25.  174 
 175 
Results 176 
Patients 177 
From August 1999 to May 2017, 149 patients with GEP NEN G3 received PRRT at 12 centers 178 
(Table 1). The primary tumor site was predominantly in the pancreas (n=89) or unknown (n=26). 179 
Other sites included the esophagus (n=2), stomach (n=4), gallbladder/common bile duct (n=2), 180 
small bowel (n=18), colon (n=3), rectum (n=3) and other abdominal sites (n=2), here collectively 181 
referred to as GI (n=34). All but two patients had metastatic disease. The median Ki-67 was 30%, 182 
ranging from 21-100%. Ki-67 21-54% was found in the majority of patients (n=125) vs. ≥ 55% 183 
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(n=23), missing for one patient. Tumor morphology was equally distributed among poorly (n=62) 184 
and well differentiated (n=60) with only few cases of intermediate differentiation classification 185 
(n=9). Seventeen of 20 patients (85%) with Ki-67% ≥ 55% vs. 44 of 110 patients (40%) with Ki-67 186 
21-54% had poorly differentiated tumor morphology. All patients with SRI showed tumor uptake, 187 
predominantly > liver uptake.  188 
 189 
Treatment 190 
At the start of PRRT, 104 patients (70%) had radiologically progressive disease (determined by 191 
RECIST in 67 patients), which also was the main indication for PRRT (65%) (Table 2). The median 192 
time from diagnosis to first PRRT was 8 months (range 0-174). PRRT was frequently given as 2nd-193 
line (n=62) or a later line of treatment (n=57). Patients received a median of 4 cycles PRRT (range 194 
1-15) with a median cumulative activity of 18 gigabecquerel (range 4-85). Radioisotopes 195 
177
Lutetium and/or 
90
Yttrium were used for PRRT in all patients other than a single patient who 196 
received 
111
Indium. Concurrent chemotherapy was applied for six patients. Overall, 98 patients 197 
(65.8%) completed their planned protocol of PRRT cycles, while 51 patients did not (Table 2). The 198 
main reasons for not completing the planned PRRT cycles were progressive disease (n=19), clinical 199 
deterioration (n=6) or toxicity (n=6). Data on treatment after PRRT was available for 118 patients 200 
(79.2%). Chemotherapy (n=65) and somatostatin analogs (n=67) were frequently used, while 201 
surgery on the primary tumor or metastases (n=8), liver embolization (n=12) and external 202 
radiotherapy (n=19) were less frequently used.  203 
 204 
Response and survival analysis 205 
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Of 114 patients evaluable by RECIST, 1 (1%) had CR, 47 (41%) PR, 43 (38%) SD and 23 (20%) 206 
PD. An example of a PR is shown in Figure 1. Disease control was seen in 79 patients (69%) 207 
responding to PRRT. RR did not differ among subgroups, including differentiation (42% vs. 43% 208 
for well and poorly differentiated, respectively) and Ki-67 index (42% vs. 43% for Ki-67 21-54% 209 
and Ki-67 ≥ 55%, respectively) (Table 3). We observed similar RR with use of 177Lu or 90Y PRRT 210 
and for patients from the 12 centers (data not shown). Median follow-up was 23 months (range 0-211 
210) and during follow-up 107 patients died. The cause of death was NEN in 91 of 94 cases with 212 
available data. The median PFS was 14 months (95%CI 10.4-17.6) and median OS was 29 months 213 
(95%CI 23.3-34.7) for all patients. Median PFS and OS were significantly longer for patients with a 214 
Ki-67 21-54% (p < 0.001), well differentiated tumor (p < 0.001), PS < 2 (p < 0.001), normal plasma 215 
levels of LDH (p < 0.001) and ALP (p < 0.001) (Figures 2-3). PFS and OS were independent of the 216 
amount of SRI tumor uptake, primary tumor site and line of treatment. In univariate analyses of PFS 217 
and OS, Ki-67 index, differentiation, PS as well as plasma LDH and ALP were statistically 218 
significant predictors (Table 4). In multivariate analysis (n=75), PS, plasma LDH and ALP were 219 
statistically significant predictors for PFS and OS, and age was significant for PFS and 220 
differentiation for OS (Table 5). Excluding plasma LDH and ALP from the multivariate analysis 221 
resulted in 106 patients in the model; differentiation and PS were statistically significant predictors 222 
for PFS and OS (data not shown).  223 
 224 
Toxicity 225 
Acute grade 3-4 toxicity occurred in 19 patients (13%), most frequently hematological (n=9) or 226 
renal (n=3) (Table 2). In four patients, the acute hematological toxicity persisted beyond the time of 227 
PRRT and was thus included as long-term toxicity as well. Another 15 patients without any acute 228 
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severe toxicity developed long-term hematological (n=11), renal (n=3) or not specified (n=1) grade 229 
3-4 toxicity. For first, second and later line of treatment 5 (17%), 16 (26%) and 13 (23%) patients 230 
had grade 3-4 toxicity, respectively. With 
177
Lu 24 (24%), 
90
Y 7 (21%) and combined 
177
Lu/
90
Y 3 231 
(25%) patients had grade 3-4 toxicity, respectively. Renal grade 3-4 toxicity occurred in two 232 
patients (6%) treated with 
90
Y and four patients (4%) treated with 
177
Lu. 233 
 234 
Discussion 235 
To the best of our knowledge, this is the largest study to assess the outcome after PRRT in patients 236 
with advanced high-grade GEP NEN. The majority of the patients had radiological progressive 237 
disease at the start of PRRT; RR was 42% and DCR was 69% for evaluable patients. A promising 238 
median PFS of 14 months and median OS of 29 months was found. Hematological or renal grade-3-239 
4 toxicity occurred in 17% of patients, not more than observed for other patient groups given PRRT. 240 
These results suggest that PRRT can be effective and tolerable in high-grade GEP NEN patients.  241 
 242 
Comparison with standard treatment  243 
The current recommendations for first-line treatment of advanced GEP NEC is systemic platinum-244 
based chemotherapy giving a RR of 30%, PFS 4-5 months and OS 11 months (Heetfeld et al. 2015; 245 
Sorbye et al. 2013; Walter et al. 2017; Yamaguchi et al. 2014). Second-line treatment for NEC is 246 
usually of short benefit with an estimated PFS of 3-4 months (Hadoux, et al. 2015; Hentic, et al. 247 
2012; Olsen, et al. 2014; Olsen, et al. 2012; Walter et al. 2017; Welin, et al. 2011). The Nordic NEC 248 
study showed a poorer RR to platinum-based chemotherapy in patients with Ki-67 < 55% (RR: 249 
15%) compared to patients with a Ki-67 ≥ 55% (RR: 42%) (Sorbye et al. 2013). Data for advanced 250 
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NET G3 are generally scarce; however, RR to platinum-based chemotherapy is low (0-17%) with a 251 
short PFS (2.4 months)(Sorbye et al. 2018). Median survival is reported to be more than 40 months 252 
but as data is presented as a mixture of stages, results are difficult to interpret (Heetfeld et al. 2015; 253 
Hijioka, et al. 2017; Sorbye et al. 2018; Velayoudom-Cephise et al. 2013). In a high-grade GEP-254 
NEN population of 136 patients, median survival from time of first diagnosis was best for NET G3 255 
(43.6 months), intermediate for NEC with a Ki-67 21-54% (24.5 months) and 5.3 months for NEC 256 
cases with a Ki-67 ≥ 55% (Milione et al. 2017). A combination of capecitabine and temozolomide 257 
has been suggested for patients with well differentiated tumor morphology and a Ki-67 21-54%, but 258 
data are scarce (Garcia-Carbonero et al. 2016; Heetfeld et al. 2015; Sorbye et al. 2018). In our 259 
cohort half the patients were treated with somatostatin analogs (SSA) either before and/or after 260 
PRRT. SSA is not recommended for high-grade NEN, but may be explained by the selection of 261 
patients with a positive SRI or use of SSA after PRRT in general.   262 
Cross-trial comparisons are difficult as well as evaluation of the benefit of PRRT without a control 263 
arm. However, a RR of 42% and DCR of 69% indicate that PRRT has an effect in our cohort. No 264 
differences in RR were observed in subgroups according to both well vs. poor differentiation and 265 
Ki-67 21-54% vs. Ki-67 ≥ 55%, as RR was approximately 40% in all subgroups. It may be that the 266 
efficacy of PRRT mediated by radiation is less sensitive to the degree of differentiation and rate of 267 
proliferation as long as the somatostatin receptor target is present on the tumor cells. The benefit of 268 
platinum based chemotherapy seems to be more dependent on a high degree of proliferation, as 269 
evident in the Nordic NEC study (Sorbye et al. 2013). As most of our patients had radiologically 270 
progressive disease at the start of PRRT, a PFS of 14 months indicates that PRRT seems to benefit 271 
many patients. Interestingly, no differences in RR, PFS and OS were evident in our cohort in regard 272 
to the line of treatment. Differentiation, Ki-67, PS, LDH and ALP were all significantly correlated 273 
to OS, as shown in previous studies (Lamarca, et al. 2017; Sorbye et al. 2013). However, the true 274 
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benefit of PRRT for PFS and especially OS is not possible to decide without a prospective 275 
randomized trial, which will be difficult to perform in such a rare disease. As implementation of 276 
PRRT may seem more likely in NET G3, such a randomized trial could compare PRRT vs standard 277 
chemotherapy regime (platinum-based or temozolomide/capecitabine) in a GEP NET G3 278 
population.  Data to clarify whether concurrent chemotherapy to PRRT should be considered is 279 
awaited (ClinicalTrials.gov: NCT02736448). Safety of PRCRT has been reported for 65 patients with 280 
5-year follow-up, showing modest reversible hematological toxicity and comparable to PRRT 281 
(Kesavan, et al. 2014).    282 
  283 
Comparison with previous PRRT data in NEN G3 and classification 284 
Three single-center retrospective studies recently reported the outcome of PRRT in NEN with a 285 
high Ki-67 and SRI tumor uptake > liver.  286 
An Australian study (Thang et al. 2018) assessed 28 patients with NEN and Ki-67 > 287 
20% (median Ki-67: 32.5%). The majority received PRRT with concurrent chemotherapy. The RR 288 
was 35%, PFS 9 months and OS 19 months for all patients. According to Ki-67 index PFS (12 vs. 4 289 
months) and OS (46 vs. 7 months) differed for Ki-67 ≤55% and Ki-67 > 55%.  290 
A German study (Zhang, et al. 2018) assessed 69 patients with GEP NEN and Ki-67 291 
index >20 % (median Ki-67 30 %). In their study, approximately one third received concurrent 292 
chemotherapy – the effect hereof was uncertain. The RR was 31 %, DCR 78 %, PFS 10 months and 293 
OS 20 months (rounded values). According to Ki-67 index PFS (11 vs. 4 months) and OS (22 vs. 7 294 
months) differed for Ki-67 ≤55% and Ki-67 > 55%.  295 
An Italian study (Nicolini, et al. 2018) assessed 33 patients with GEP NEN and Ki-67 296 
index of 15-70% (median Ki-67: 25%). The RR was 6%, PFS 23 months and OS 52.9 months.  297 
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Overall, in our study we found similar results:  PFS (16 vs.6 months) and OS (31 vs.9 months) 298 
differed significantly in patients with Ki-67 < 55% vs. Ki-67 ≥ 55%.  299 
 In general, the likelihood of somatostatin receptor expression on neuroendocrine cells 300 
decreases with increasing grade of tumor, whereas the opposite applies for FDG uptake (Binderup, 301 
et al. 2010; Hicks, et al. 2017). NET G3 seems to have a positive SRI uptake in 70% of cases, 302 
whereas for NEC the figure is more likely 30% (Heetfeld et al. 2015; Raj et al. 2017; Sorbye et al. 303 
2018; Sorbye et al. 2013; Velayoudom-Cephise et al. 2013).  Preliminary studies have also shown 304 
the effectiveness of PRRT in patients with a more aggressive grade NEN with 
18
F-FDG-avid and 305 
SRI uptake (Kashyap, et al. 2015). Patients with concordant 
18
F-FDG and SRI avid lesions may be 306 
more radiosensitive by having a high proliferative fraction.  Few of the patients in our cohort had 307 
18
F-FDG PET/CT data available limiting further analysis.  308 
As previously reported (Basturk, et al. 2015), the grading of NEN according to Ki-67 309 
may be optimized by further subclassification of patients with Ki-67 > 20%. In the current study of 310 
patients graded as NEN G3 based on Ki-67, nearly half the patients had well-differentiated tumor 311 
morphology. The majority of patients with well-differentiated tumors also had Ki-67 21-54%. There 312 
was a marked difference in outcomes in our cohort when comparing subgroups based on tumor 313 
morphology:  PFS (19 vs.8 months) and OS (44 vs.19 months) differed significantly comparing 314 
well differentiated vs. poorly-differentiated neoplasms. 315 
 316 
Toxicity 317 
In our study, 26 patients (17%) had either acute or long-term grade 3-4 renal or hematological 318 
toxicity. This is similar to that reported in other larger retrospective analysis of patient groups given 319 
PRRT (Imhof et al. 2011; Kwekkeboom et al. 2008), although in NETTER-1 no evidence of renal 320 
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adverse effects was observed in patients treated with 
177
Lu (Strosberg et al. 2017). We observed 321 
renal toxicity both in patients treated with 
90
Y and 
177
Lu. Furthermore, we found similar frequency 322 
of toxicity for patients receiving PRRT as first line vs. later line of treatment. 323 
 324 
Limitations 325 
High-grade GEP NEN patients treated with PRRT are probably highly selected on factors as being 326 
positive on SRI imaging and having a rather low median Ki-67 compared to the NEN G3 group as a 327 
whole. RR, PFS and OS should be interpreted carefully in light of the retrospective design of the 328 
study. However most of our patients were classified as having radiological progression of disease at 329 
the start of PRRT, and approximately half were based on RECIST. The rate of side-effects of PRRT 330 
in our analysis was in line with that previously reported for PRRT, but toxicity reports in a 331 
retrospective study must be interpreted cautiously. Pathologist reports were mainly from NET 332 
expert centers and reclassification was done in reports with missing data when sections were 333 
available. Though, a general problem is that the distinction between well and poor differentiation is 334 
not standardized (Tang, et al. 2016). Addition of molecular data on DAXX, ATRX (loss of 335 
expression in well-differentiated tumors) and Rb1, KRAS and p53 (expressed in poorly-336 
differentiated tumors, could aid further in classification of differentiation (Sorbye et al. 2018).  337 
 338 
Conclusion 339 
This large retrospective multicenter study is at present the most comprehensive report on which to 340 
base treatment decisions regarding the use of PRRT in high-grade GEP NEN. It shows promising 341 
RR, DCR, PFS and OS and acceptable toxicity after PRRT in patients with mainly progressive 342 
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disease. This suggests that PRRT is active and potentially effective in patients with GEP NEN G3. 343 
Awaiting further data, PRRT may therefore be a treatment option for GEP NEN G3 patients.  344 
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Table 1. Baseline characteristics of 149 patients with GEP NEN G3 receiving PRRT.  486 
Characteristics Value 
Age (years), median (range) 57 (24-85) 
Time since diagnosis (m), median (range) 8 (0-174) 
Gender, n (%): Male 
   Female 
76 (51.0) 
73 (49.0) 
PS, n (%): 0 
                 1 
                 2 
                 Missing 
74 (49.7) 
41 (27.5) 
11 (7.4) 
23 (15.4) 
Primary tumor site, n (%): Pancreas  
                     Gastrointestinal 
                     Unknown primary 
89 (59.7) 
34 (22.8) 
26 (17.4) 
Metastatic disease, n (%) 
                      Liver metastases 
147 (98.7) 
141 (94.6) 
Tumor differentiation, n (%): Well 
                           Intermediate 
                           Poor 
                           Not specified 
60 (40.3) 
9 (6.0) 
62 (41.6) 
18 (12.1) 
Ki-67 (%), median (range) 
                   21-54% 
                   ≥ 55% 
                   Not specified 
30 (21-100) 
125 (83.9) 
23 (15.4) 
1 (0.7) 
Ki-67 and differentiation: NET G3 
                NEC; Ki-67 21-54%  
                NEC; Ki-67 ≥ 55%  
                Not specified 
58 (38.9) 
44 (29.5) 
17 (11.4) 
30 (20.1) 
CgA staining of tumor: Strongly positive 
                 Partly positive 
                 Negative 
                 Not specified 
90 (60.4) 
19 (12.8) 
9 (6.0) 
31 (20.8) * 
Synaptophysin staining of tumor: Strongly positive 
                                 Partly positive 
                                 Not specified  
105 (70.5) 
11 (7.4) 
33 (22.1) 
SRI available 
Uptake: None 
              < liver 
              = liver 
              > liver 
146 (98.0%) 
0 
5 (3.4%) 
10 (6.7%) 
131 (87.9%) 
18
F-FDG PET/CT available 
Tumor positive 
39 (26.2%) 
34 (87.2%) 
Plasma-CgA (n, %): Normal 
            Elevated  
            Missing
 
15 (10.1) 
83 (55.7) 
51 (34.2) 
Plasma-LDH, n(%): Normal 
            Elevated 
            Missing 
76 (51.0) 
35 (23.5) 
38 (25.5) 
Plasma-ALP, n (%): Normal 
            Elevated 
            Missing 
54 (36.2) 
67 (45.0) 
28 (18.8) 
Number of prior lines of medical treatment: 0 
                                                 1 
                                                 2 
                                                 > 2 
30 (20.1) 
62 (41.6) 
31 (20.8) 
26 (17.5 
Prior treatment, n (%)  
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Primary tumor resected 
Somatostatin analog 
Chemotherapy/targeted therapy 
Cisplatin 
Carboplatin 
Etoposide 
Capecitabine or 5-fluorouracil 
Temozolomide 
Streptozotocin 
Everolimus 
Doxorubicin 
Sunitinib 
Oxaliplatin 
Interferon  
58 (38.9) 
74 (49.7)** 
88 (59.1) 
31 (20.8) 
26 (17.4) 
46 (30.9) 
38 (25.5) 
19 (12.8) 
13 (8.7) 
9 (6.0) 
5 (3.4) 
4 (2.7) 
4 (2.7) 
2 (1.3) 
PS: Performance status. CgA: chromogranin A. SRI: Somatostatin receptor imaging. LDH: lactate dehydrogenase. 487 
ALP: alkaline phosphatase.  488 
* In 29 patients, CgA and synaptophysin staining results were not available; hereof 28 patients had SRI available that 489 
showed tumor uptake.   490 
**Missing values for seven patients.  491 
  492 
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Table 2. Treatment details and toxicity of PRRT for 149 patients with GEP NEN G3.  493 
 Value 
Radiologically progressive disease at start of PRRT, n (%) 
No 
Unknown 
104 (69.8) 
35 (23.5) 
10 (6.7) 
Indication for PRRT, n (%) 
Progression of disease 
First line 
Side effects to other therapies 
Other 
 
97 (65.1) 
30 (20.1) 
6 (4.0) 
16 (10.7) 
Radioisotope, n (%) 
177
Lutetium 
90
Yttrium 
177
Lutetium + 
90
Yttrium 
111
Indium 
Not specified 
 
101 (67.8) 
34 (22.8) 
12 (8.1) 
1 (0.7) 
1 (0.7) 
Cumulative activity (GBq), median (range)  18.0 (4-85) 
Number of PRRT cycles, median (range) 4.0 (1-15) 
Fulfilled planned number of cycles 
Discontinuation of PRRT: 
Disease progression  
Clinical deterioration 
Hematological side effects 
Renal side effects 
Lack of compliance 
Other 
Not specified 
98 (65.8) 
 
19 (12.8) 
6 (4.0) 
5 (3.4) 
1 (0.7) 
1 (0.7) 
17 (11.4) 
 2 (1.3) 
WHO performance status after treatment, n (%) 
0 
1 
2 
3 
Not specified 
 
74 (49.7) 
34 (22.8) 
11 (7.4) 
5 (3.4) 
25 (16.8) 
Absence of acute toxicity (grade 3-4), n (%) 
Acute toxicity  
Hematological, grade 3/grade 4, n * 
Renal 
Diarrhea 
Nausea 
Other, not specified 
Unknown 
121 (81.2) 
19 (12.8) 
8/1 
2/1 
0/2 
0/2 
14/1 
9 (6.0) 
Absence of long-term toxicity (grade 3-4), n (%) 
Long-term toxicity 
Hematological, grade 3/grade 4, n * 
Renal 
Other, not specified 
Unknown 
101 (67.8) 
19 (12.8) 
13/2 
3/0 
3/3 
29 (19.5) 
*More than one may be reported for a patient.  494 
 495 
 496 
 497 
                          Table 3. PRRT response rates (n=114) and outcomes (n=149) in GEP NEN G3.   498 
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 499 
*Denotes statistically significant difference in PFS and OS. P-values as shown in Figures 1-2.  500 
 501 
 502 
CR: complete response. PR: partial response. SD: stable disease. PD: progressive disease per Response Evaluation 503 
Criteria In Solid Tumours. PFS: progression-free survival. OS: overall survival. CI: confidence interval. SRI: 504 
somatostatin receptor imaging. LDH: lactate dehydrogenase. ALP: alkaline phosphatase.  505 
 506 
 507 
 508 
 509 
 CR 
(%) 
PR  
(%) 
SD  
(%) 
PD  
(%) 
PFS (m),  
(95% CI) 
OS (m), 
 (95% CI) 
 
All patients 1 (1) 47 (41) 43 (38) 23 (20) 14.0 (10.4-17.6) 29.0 (23.3-34.7)  
PS 
 0 
 1 
 2 
 
1 (2) 
0 
0 
 
21 (36) 
17 (53) 
3 (38) 
 
26 (45) 
8 (25) 
2 (25) 
 
10 (17) 
7 (22) 
3 (38) 
 
16.0 (11.0-21.0) 
14.0 (8.2-19.8) 
3.0 (0-6.2) 
 
39.0 (28.1-49.9) 
23.0 (16.2-29.8) 
4.0 (0-12.6) 
 
* 
SRI tumor uptake 
 ≤liver 
 > liver 
 
1 (9) 
0 
 
3 (27) 
44 (43) 
 
4 (36) 
38 (37) 
 
3 (27)  
20 (20) 
 
16.0 (7.9-24.1) 
14.0 (10.0-18.0) 
 
25.0 (8.6-41.4) 
29.0 (21.6-36.4) 
 
Primary tumor site 
 Pancreas 
 Gastrointestinal 
 Unknown 
 
0 
0 
1 (5) 
 
32 (48) 
11 (42) 
4 (19) 
 
23 (34) 
9 (35) 
11 (52) 
 
12 (18) 
6 (23) 
5 (24) 
 
14.0 (10.4-17.6) 
10.0 (0-21.2) 
16.0 (8.4-23.6) 
 
29.0 (21.7-36.3) 
31.0 (7.5-54.5) 
29.0 (11.4-46.6) 
 
Differentiation 
 Well 
 Poor 
 
0 
1 (2) 
 
19 (42) 
21 (41)  
 
23 (51) 
13 (25) 
 
3 (7) 
16 (31)  
 
19.0 (13.9-24.1) 
8.0 (3.3-12.7) 
 
44.0 (25.2-62.8) 
19.0 (11.7-26.3) 
 
* 
Proliferation 
 Ki-67 21-54% 
 Ki-67≥ 55% 
 
1 (1) 
0 
 
41 (41) 
6 (43) 
 
41 (41) 
2 (14) 
 
16 (16) 
6 (43) 
 
16.0 (12.7-19.3) 
6.0 (3.0-9.0) 
 
31.0 (24.2-37.8) 
9.0 (4.5-13.5) 
 
* 
Differentiation and 
proliferation 
 NET G3 
 NEC; Ki-67 21-54% 
 NEC; Ki-67 ≥ 55% 
 
 
0 
1 (3) 
0 
 
 
18 (42)  
16 (41) 
5 (45) 
 
 
22 (51) 
12 (31) 
1 (9) 
 
 
3 (7) 
10 (26) 
5 (45) 
 
 
19.0 (14.4-23.6) 
11 (5.4-16-6) 
4 (0.8-7.2) 
 
 
44 (25.3-62.7) 
22.0 (16.0-28.0) 
9.0 (1.6-16.4) 
 
* 
Line of treatment 
 First line 
 Second line 
 Later line 
 
0 
0 
1 (2) 
 
10 (42) 
20 (45) 
17 (37) 
 
9 (38) 
16 (36) 
18 (39) 
 
5 (21) 
8 (18) 
10 (22) 
 
13 (6.3-19.7) 
12.0 (6.5-17.5) 
19.0 (13.6-24.4) 
 
29 (12.5-45.5) 
29 (16.8-41.2) 
29.0 (18.0-40.0) 
 
plasma-LDH 
 Normal 
 Elevated 
 
1 (2) 
0 
 
30 (48) 
8 (30) 
 
24 (38) 
8 (30) 
 
8 (13) 
11 (41) 
 
18.0 (14.3-21.7) 
4.0 (0.5-7.5) 
 
39.0 (30.8-47.2) 
13.0 (7.4-18.6) 
 
* 
plasma-ALP 
 Normal 
 Elevated 
 
1 (2) 
0 
 
21 (47) 
22 (40) 
 
18 (40) 
19 (35) 
 
5 (11) 
14 (25) 
 
18.0 (9.9-26.1) 
14.0 (9.2-18.8) 
 
39.0 (30.8-47.2) 
21.0 (16.8-25.2) 
 
* 
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Table 4. Multiple Cox regression analysis of predictors for PFS and OS in 75 GEP NEN G3 510 
patients treated with PRRT. (74 missing) 511 
Model 1  PFS OS 
Covariate Hazard ratio 
(95% CI) 
P-value Hazard ratio 
(95% CI) 
P-value 
Age 0.98 (0.95-1.00) 0.045 0.99 (0.96-1.02) 0.42 
Male 1.53 (0.85-2.74) 0.16 1.05 (0.53-2.10) 0.89 
PS 0 1  1  
1 2.57 (1.33-4.93) 0.005 2.35 (1.13-4.89) 0.02 
2 3.42 (0.90-13.06) 0.07 4.20 (0.98-18.01) 0.05 
SRI ≤ liver 0.72 (0.13-4.03) 0.70 0.43 (0.04-4.33) 0.47 
Primary tumor site (unknown primary) 1  1  
Gastrointestinal 0.80 (0.32-2.02) 0.64 0.78 (0.26-2.37) 0.66 
Pancreas  0.66 (0.28-1.57) 0.35 0.46 (0.18-1.22) 0.12 
Poorly differentiated 1.69 (0.88-3.23) 0.11 2.92 (1.31-6.50) 0.009 
Ki-67 ≥ 55% 1.11(0.51-2.42) 0.80 1.97 (0.83-4.66) 0.13 
Line of treatment (first line) 
1  1  
Second line 
0.76 (0.38-1.54) 0.46 1.55 (0.70-3.43) 0.28 
Later line 
1.04 (0.48-2.27) 0.91 1.77 (0.67-4.65) 0.25 
Elevated plasma-LDH  
2.66 (1.29-5.49) 0.008 2.61 (1.16-5.90) 0.02 
Elevated plasma-ALP 
2.24 (1.22-4.09) 0.009 2.79 (1.42-5.49) 0.003 
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Supplementary Table 1. Univariate analyses of predictors for PFS and OS in 149 GEP NEN 522 
G3 patients treated with PRRT.  523 
 PFS OS 
Covariate Hazard ratio 
(95% CI) 
P-value Hazard ratio 
(95% CI) 
P-value 
Age 1.00 (0.99-1.02) 0.84 1.01 (0.99-1.03) 0.20 
Male 0.96 (0.68-1.34) 0.79 0.78 (0.53-1.1) 0.19 
PS 0 1  1  
1 1.36 (0.91-2.04) 0.14 1.65 (1.04-2.63) 0.04 
2 3.53 (1.83-6.83) < 0.001 6.84 (3.40-13.76) < 0.001 
SRI ≤ liver 1.17 (0.67-2.04) 0.59 0.79 (0.40-1.57) 0.50 
Primary tumor site (unknown primary) 1  1  
Gastrointestinal 1.13 (0.65-1.95) 0.67 0.75 (0.41-1.39) 0.36 
Pancreas  1.29 (0.80-2.07) 0.30 0.83 (0.50-1.37) 0.46 
Poorly differentiated 1.62 (1.11-2.36) 0.01 2.55 (1.62-4.02) < 0.001 
Ki-67 ≥ 55% 2.15 (1.34-3.47) 0.002 2.48 (1.51-4.06) < 0.001 
Differentiation and proliferation (NET G3) 
1  1  
NEC; Ki-67 21-54% 
1.38 (0.91-2.07) 0.13 2.06 (1.26-3.39) 0.004 
NEC; Ki-67 ≥ 55% 
2.81 (1.55-5.11) 0.001 4.77 (2.51-9.06) < 0.001 
Line of treatment (first line) 
1  1  
Second line 
1.08 (0.69-1.69) 0.73 1.04 (0.63-1.71) 0.87 
Later line 
0.79 (0.50-1.24) 0.31 0.86 (0.52-1.42) 0.55 
Elevated plasma-LDH  
2.35 (1.54-3.59) < 0.001 3.14 (1.96-5.02) < 0.001 
Elevated plasma-ALP 
1.53 (1.04-2.24) 0.03 2.21 (1.42-3.45) < 0.001 
CI: Confidence interval. PS: performance status. SRI: Somatostatin receptor imaging. GI: gastrointestinal. LDH: lactate 524 
dehydrogenase. ALP: alkaline phosphatase. 525 
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Supplementary table 2. Multiple Cox regression analysis of predictors for PFS and OS in 106 532 
GEP NEN G3 patients treated with PRRT. (43 missing) 533 
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 534 
Model 2  PFS OS 
Covariate Hazard ratio 
(95% CI) 
P-value Hazard ratio 
(95% CI) 
P-value 
Age 1.00 (0.99-1.02) 0.66 1.02 (0.99-1.04) 0.16 
Male 1.13 (0.71-1.80) 0.60 0.86 (0.48-1.54) 0.62 
PS 0 1  1  
1 1.74 (1.07-2.86) 0.03 1.86 (1.07-3.24) 0.03 
2 4.10 (1.82-9.24) < 0.001 5.39 (2.15-13.52) < 0.001 
SRI ≤ liver 0.86 (0.33-2.21) 0.75 0.16 (0.02-1.20) 0.07 
Primary tumor site (unknown primary) 1  1  
Gastrointestinal 1.01 (0.50-2.01) 0.98 0.51 (0.23-1.11) 0.09 
Pancreas  1.16 (0.63-2.12) 0.63 0.62 (0.32-1.19) 0.15 
Poorly differentiated 1.84 (1.16-2.94) 0.01 3.16 (1.73-5.76) < 0.001 
Ki-67 ≥ 55% 1.30 (0.68-2.48) 0.43 1.69 (0.81-3.52) 0.16 
Line of treatment (first line) 
1  1 0.19 
Second line 
1.15 (0.64-2.07) 0.63 1.55 (0.78-3.10) 0.21 
Later line 
0.75 (0.40-1.43) 0.39 0.98 (0.45-2.13) 0.95 
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Figure 1. Kaplan-Meier curves of PFS for 149 patients with GEP NEN G3 treated with 536 
PRRT. Stratification by Ki-67 index (n=148), differentiation (n=122), performance status 537 
(n=126), combined Ki-67 index and differentiation (n=119), LDH (n=111) and ALP (n=121), 538 
respectively. P-values shown in figures for statistically significant differences.   539 
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Figure 2. Kaplan-Meier analysis of OS for 149 patients with GEP NEN G3 treated with 571 
PRRT. Stratification by Ki-67 index (n=148), differentiation (n=122), performance status 572 
(n=126), combined Ki-67 index and differentiation (n=119), LDH (n=111) and ALP (n=121), 573 
respectively. P-values shown in figures for statistically significant differences.   574 
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